Cronos Group Inc., (NASDAQ: CRON) a global cannabinoid company, has reported an increase in net revenue for the first quarter of 2024. The company's net revenue surged by 30%, reaching $25.3 million, driven primarily by sales in Canada and Israel. Despite this revenue upswing, Cronos posted a net loss of $2.48 million for the quarter, an improvement from the $18.04 million loss reported in the same period last year. Gross profits rose to $4.48 million, marking a 53% increase year-over-year with a rise in gross margin to 18%. Cronos's adjusted EBITDA, showing a reduction in losses, decreased to $10.67 million from $15.68 million in Q1 2023. This reduction reflects Cronos's cost-control measures and operational efficiencies implemented during the period. Additionally, the company's balance sheet showed $855 million ...